Cambridge, UK based Mestag Therapeutics last month announced a license and research collaboration with MSD to leverage the company's fibroblast platform to find inflammatory disease targets

CEO Susan Hill describes the role that fibroblasts play in regulating immune responses to inflammatory conditions and how Mestag is leveraging this in drug development. It now has the partnership with MSD, as well as a prior one with Janssen, and it's own assets in oncology and autoimmune disease.

Recent Posts

See All

Microbiotica is working on microbiome therapies in Cambridge, UK, with lead programs in immuno-oncology and inflammatory bowel disease

Tokyo based TMS has a lead program that aims to be the first new medicine for acute ischemic stroke in decades

Tokyo based Heartseed is leveraging its expertise iPSCs and regenerative medicine to solve unmet needs in cardiovascular disease like heart failure

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh